These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 14630079

  • 1. Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia.
    Chang H, Salma F, Yi QL, Patterson B, Brien B, Minden MD.
    Leuk Res; 2004 Jan; 28(1):43-8. PubMed ID: 14630079
    [Abstract] [Full Text] [Related]

  • 2. Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy.
    Hu XM, Liu F, Zheng CM, Li L, Liu C, Zhang SS, Xiao HY, Yang XH, Wang HZ, Xu YG, Hu NP, Ma R.
    Chin J Integr Med; 2009 Jun; 15(3):193-7. PubMed ID: 19568712
    [Abstract] [Full Text] [Related]

  • 3. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
    Löwenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R, Dekker AW, Berneman ZN, Thyss A, van der Lelie J, Sonneveld P, Visani G, Fillet G, Hayat M, Hagemeijer A, Solbu G, Zittoun R.
    J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
    [Abstract] [Full Text] [Related]

  • 4. The prognostic significance of chromosomal analysis and immunophenotyping in 117 patients with de novo acute myeloid leukemia.
    de Nully Brown P, Jurlander J, Pedersen-Bjergaard J, Victor MA, Geisler CH.
    Leuk Res; 1997 Oct; 21(10):985-95. PubMed ID: 9403009
    [Abstract] [Full Text] [Related]

  • 5. The significance of CD34 and TdT determinations in patients with untreated de novo acute myeloid leukemia.
    Lee EJ, Yang J, Leavitt RD, Testa JR, Civin CI, Forrest A, Schiffer CA.
    Leukemia; 1992 Nov; 6(11):1203-9. PubMed ID: 1279324
    [Abstract] [Full Text] [Related]

  • 6. P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia.
    Del Poeta G, Venditti A, Stasi R, Aronica G, Cox MC, Buccisano F, Tamburini A, Bruno A, Maurillo L, Battaglia A, Suppo G, Epiceno AM, Del Moro B, Masi M, Amadori S, Papa G.
    Leuk Res; 1999 May; 23(5):451-65. PubMed ID: 10374859
    [Abstract] [Full Text] [Related]

  • 7. Prognostic value of cell marker analysis in de novo acute myeloid leukemia.
    Del Poeta G, Stasi R, Venditti A, Suppo G, Aronica G, Bruno A, Masi M, Tabilio A, Papa G.
    Leukemia; 1994 Mar; 8(3):388-94. PubMed ID: 7907393
    [Abstract] [Full Text] [Related]

  • 8. High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission.
    Stein AS, O'Donnell MR, Slovak ML, Nademanee A, Dagis A, Schmidt GM, Parker PM, Snyder DS, Smith EP, Somlo G, Margolin KA, Arber D, Niland J, Forman SJ.
    Leukemia; 2000 Jul; 14(7):1191-6. PubMed ID: 10914541
    [Abstract] [Full Text] [Related]

  • 9. Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.
    Tavernier E, Le QH, Elhamri M, Thomas X.
    Leuk Res; 2003 Mar; 27(3):205-14. PubMed ID: 12537972
    [Abstract] [Full Text] [Related]

  • 10. Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia.
    Venditti A, Del Poeta G, Buccisano F, Tamburini A, Cox-Froncillo MC, Aronica G, Bruno A, Del Moro B, Epiceno AM, Battaglia A, Forte L, Postorino M, Cordero V, Santinelli S, Amadori S.
    Leukemia; 1998 Jul; 12(7):1056-63. PubMed ID: 9665190
    [Abstract] [Full Text] [Related]

  • 11. Relevance of immunophenotypes to prognostic subgroups of age, WBC, platelet count, and cytogenetics in de novo acute myeloid leukemia.
    Li X, Li J, Du W, Zhang J, Liu W, Chen X, Li H, Huang S, Li X.
    APMIS; 2011 Jan; 119(1):76-84. PubMed ID: 21143529
    [Abstract] [Full Text] [Related]

  • 12. Clinical review on features and cytogenetic patterns in adult acute myeloid leukemia with lymphoid markers.
    Cuneo A, Ferrant A, Michaux JL, Boogaerts M, Demuynck H, Bosly A, Doyen C, Carli MG, Piva N, Castoldi G.
    Leuk Lymphoma; 1993 Mar; 9(4-5):285-91. PubMed ID: 8348065
    [Abstract] [Full Text] [Related]

  • 13. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22).
    Baer MR, Stewart CC, Lawrence D, Arthur DC, Byrd JC, Davey FR, Schiffer CA, Bloomfield CD.
    Blood; 1997 Aug 15; 90(4):1643-8. PubMed ID: 9269784
    [Abstract] [Full Text] [Related]

  • 14. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.
    Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, Head DR, Appelbaum FR, Willman CL.
    Blood; 1997 May 01; 89(9):3323-9. PubMed ID: 9129038
    [Abstract] [Full Text] [Related]

  • 15. [Clinical Features and Prognosis of 227 cases of Acute Myeloid Leukemia with Cross-lineage Antigen Expression].
    Fang F, Zhu P, Zhang Y, Lu XZ, Dong YJ, Sun YH, Wang LH, Bu DF, Cen XN, Wang MJ.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug 01; 24(4):990-7. PubMed ID: 27531762
    [Abstract] [Full Text] [Related]

  • 16. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
    Liu J, Mi Y, Fu M, Yu W, Wang Y, Lin D, Bian S, Wang J.
    Am J Hematol; 2009 Jul 01; 84(7):422-7. PubMed ID: 19484734
    [Abstract] [Full Text] [Related]

  • 17. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
    Plesa C, Chelghoum Y, Plesa A, Elhamri M, Tigaud I, Michallet M, Dumontet C, Thomas X.
    Cancer; 2008 Feb 01; 112(3):572-80. PubMed ID: 18085638
    [Abstract] [Full Text] [Related]

  • 18. Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group.
    Bradstock K, Matthews J, Benson E, Page F, Bishop J.
    Blood; 1994 Aug 15; 84(4):1220-5. PubMed ID: 8049437
    [Abstract] [Full Text] [Related]

  • 19. Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients.
    Colovic M, Colovic N, Radojkovic M, Stanisavljevic D, Kraguljac N, Jankovic G, Tomin D, Suvajdzic N, Vidovic A, Atkinson HD.
    Ann Hematol; 2012 Sep 15; 91(9):1363-70. PubMed ID: 22592651
    [Abstract] [Full Text] [Related]

  • 20. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
    Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD, Cancer and Leukemia Group B (CALGB 8461).
    Blood; 2002 Dec 15; 100(13):4325-36. PubMed ID: 12393746
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.